Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King/Mylan Merger Will Provide Critical Mass To Develop Palatin ED Agent

Executive Summary

Mylan's acquisition of King will provide the critical mass necessary to develop PT-141, a Phase II intranasal sexual dysfunction agent in-licensed from Palatin, King said

You may also be interested in...



King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans

King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan

King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans

King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan

Mylan Places Big Bet On Antihypertensives: $4 Bil. Deal For King

Mylan's proposed acquisition of King is a big move by the generic company to carve out a leading position in the branded antihypertensive market

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel